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We previously reported that alveolar macrophages from patients with chronic obstructive
pulmonary disease (COPD) are defective in their ability to phagocytose apoptotic cells, with
a similar defect in response to cigarette smoke. The exact mechanisms for this defect are
unknown. Sphingolipids including ceramide, sphingosine and sphingosine-1-phosphate
(S1P) are involved in diverse cellular processes and we hypothesised that a comprehensive
analysis of this system in alveolar macrophages in COPDmay help to delineate the reasons
for defective phagocytic function.
Methods
We compared mRNA expression of sphingosine kinases (SPHK1/2), S1P receptors
(S1PR1-5) and S1P-degrading enzymes (SGPP1, SGPP2, SGPL1) in bronchoalveolar
lavage-derived alveolar macrophages from 10 healthy controls, 7 healthy smokers and 20
COPD patients (10 current- and 10 ex-smokers) using Real-Time PCR. Phagocytosis of
apoptotic cells was investigated using flow cytometry. Functional associations were
assessed between sphingosine signalling system components and alveolar macrophage
phagocytic ability in COPD. To elucidate functional effects of increased S1PR5 on macro-
phage phagocytic ability, we performed the phagocytosis assay in the presence of varying
concentrations of suramin, an antagonist of S1PR3 and S1PR5. The effects of cigarette
smoking on the S1P system were investigated using a THP-1 macrophage cell line model.
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Results
We found significant increases in SPHK1/2 (3.4- and 2.1-fold increases respectively),
S1PR2 and 5 (4.3- and 14.6-fold increases respectively), and SGPL1 (4.5-fold increase) in
COPD vs. controls. S1PR5 and SGPL1 expression was unaffected by smoking status, sug-
gesting a COPD “disease effect” rather than smoke effect per se. Significant associations
were noted between S1PR5 and both lung function and phagocytosis. Cigarette smoke
extract significantly increased mRNA expression of SPHK1, SPHK2, S1PR2 and S1PR5 by
THP-1 macrophages, confirming the results in patient-derived macrophages. Antagonising
SIPR5 significantly improved phagocytosis.
Conclusion
Our results suggest a potential link between the S1P signalling system and defective mac-
rophage phagocytic function in COPD and advise therapeutic targets.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
worldwide. Cigarette smoking is a major cause of COPD, yet despite the huge campaign that
encourages smoking cessation worldwide, the smoking incidence is only slowly decreasing in
developed countries and still increasing in developing countries. COPD is an incurable disease
and currently available treatments are largely ineffective [1,2]. There is therefore an urgent
need for further understanding the pathophysiology of COPD to advise effective new
therapies.
In previous studies our group has shown that alveolar macrophages from COPD patients
are defective in their ability to phagocytose apoptotic cells despite smoking cessation (defective
efferocytosis) [3–7]. We and others have shown that if these apoptotic cells are not cleared
effectively by alveolar macrophages, they may undergo secondary necrosis which can further
promote the inflammation in the lung [8,9]. We have also shown that both alveolar macro-
phages and monocyte-derived macrophages from COPD patients are impaired in their ability
to phagocytose bacteria which might potentially contribute to bacterial colonization in COPD
[10]. Numerous molecules have been identified as possible contributors to these macrophage
phenomena in COPD [11], but the exact mechanism is yet unknown.
Sphingolipid metabolites including ceramide, sphingosine andsphingosine-1-phosphate
(S1P) are involved in diverse cellular processes. Phosphorylation of sphinosine by the sphingo-
sine kinases (SPHKs) results in the production of S1P, while its acetylation by ceramide
synthase produces ceramide, and then sphingomyelin after sphingomyelin synthase catalysed
coupling to phosphocholine. Structural changes in these molecules have been proven to result
in modulation of cellular function [11]. Many sphingolipid molecules have been linked to
inflammatory lung diseases and used as potential therapeutic targets, such as acid sphingomye-
linase in acute lung injury [12], neutral sphingomyelinase-2 in COPD [13], and ceramide in
cystic fibrosis [14].
We have previously shown that human lung tissue comprises a complex expression profile
for the individual components of the S1P signalling system including synthesising enzymes,
receptors and degrading enzymes [15]. In COPD we found correlations between mRNA
expression levels of several receptors and enzymes involved in the S1P signalling system in the
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lung suggesting common regulatory mechanisms. However, we did not assess individual lung
cells such as alveolar macrophages, which are likely to be of importance in COPD. S1P is one
of the most important sphingolipid molecules and its role in immune cell function has been
shown in many studies [16,17]. It has been shown to be involved in a multitude of cellular sig-
nalling pathways and responses, such as proliferation, survival and growth [18] and exerts its
function through five G-protein coupled receptors (S1PR1-5) [19].
The alveolar macrophage is a very interesting target for our investigations since it has been
shown that S1P regulates macrophage function, phagosome maturation and migration [20].
The phagocytic function of macrophages has also been shown to be modulated by the sphingo-
sine system; for example, it has been shown that phagocytosis ofM.tuberculosis bacteria
depends on SPHK1 [21]. S1P which has been implicated in macrophage actin assembly and
phagosome function [22] was shown to improve phagocytosis of Cryptococcus neoformans
when exogenously added to wild-type alveolar macrophages [23]. Furthermore, ceramide, the
precursor of S1P, has an opposing role to S1P and has been found to decrease macrophage
efferocytosis in COPD [24]. Taken together, these studies suggest that defective efferocytosis in
alveolar macrophages in COPD may be associated with the S1P system. Despite the numerous
studies on this system and its role in inflammation and diseases, to the best of our knowledge,
there have been no comprehensive studies of the S1P system in macrophages from healthy con-
trols, or of the role of this system in the defective macrophage function in COPD. In this study,
we compared the expression of components of the S1P-signalling system in alveolar macro-
phages from healthy control volunteers and COPD patients. We determined the expression
profiles of SPHK1, SPHK2, receptors (S1PR1-5) and the S1P-degrading enzymes, sphingosine-
1-phosphate phosphatase 1 and 2 (SGPP1 and SGPP2) and sphingosine-1-phosphate lyase 1
(SGPL1) and their correlation with the ability of alveolar macrophages to phagocytose apopto-
tic cells. We further investigated functional consequences of smoking on the expression profile
of the S1P system in current- or ex-smoking COPD subjects and by using an in vitro THP-1
macrophage cell line model.
Material and Methods
Categorization of patients
This study was approved by the Royal Adelaide Hospital Ethics Committee (Adelaide, Austra-
lia) and informed written consent was obtained for each subject in this study. Patients were cat-
egorized based on gender, smoking status, age, the presence of lung cancer and lung function
(Table 1). The diagnosis of COPD was carried out according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) standards. Any subject who had ceased smoking
within the previous 6 months was included in the ‘current smoker’ groups. Exclusion criteria
included diagnosis of other inflammatory lung diseases, blood malignancy and current
infection.
Bronchoalveolar lavage (BAL) and isolation of macrophages
Bronchoscopy was performed according to American Thoracic Society recommendations for
the performance of bronchoscopy for investigative purposes, as previously described [25]. BAL
was collected then centrifuged at 1600 RPM for 5 min and the supernatant frozen for later use.
Macrophages were isolated by adhering to plastic as previously described, concentration
adjusted to 4×10(5) cells/ml [3] then either used for phagocytosis or frozen immediately at
-80°C for gene expression analysis.
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Cell culture and stimulation
THP-1monocytes (ATCC, Manassas, VA, USA) were differentiated into macrophages by seed-
ing the cells at a density of 4×10(5) cells/mL in 24 well plastic plates, then stimulating with
100nM phorbol 12-myristate 13-acetate [26] in RPMI 1640 medium at 37°C with 5% CO2 for
72 has previously described [27]. Experiments were carried out between passages 6 and 20.
Exposure of THP-1 macrophages to cigarette smoke extract was carried as previously
described [4,5,28,29]. After cigarette smoke extract exposure, non-adherent cells were dis-
carded, and adherent cells were incubated with 500μL cold PBS for 5 min, then harvested by
scraping the adherent cells with a plastic scraper into a 1.5 mL tubes prior to centrifugation at
4°C at 1600 RPM. Supernatant was removed and cell pellet stored at– 80°C for mRNA expres-
sion analysis.
Reverse transcription and quantitative real-time PCR (qPCR)
The total RNA was extracted from snap frozen alveolar macrophages or THP-1 macrophages
using the RNeasy Mini Kit (Qiagen, Doncaster, Australia) according to the manufacturer’s
instructions. The concentration of total RNA was determined using standard photospectome-
try. The RNA quality expressed as RIN number was determined using the RNA Pico-Chip and
Agilent 2100 Bioanalyzer (Agilent Technologies, Forest Hill, Australia). Complementary DNA
(cDNA) was synthesized using RT2 HT First Strand Kit (Qiagen). Synthesized cDNA was
stored at −20°C. The qPCR analyses of the samples were performed using Custom RT2 Profiler
PCR arrays (Qiagen) and the ABI sequence detection system (StepOne Plus) as previously
described [15], with modifications. Briefly, a 25μL reaction mixture into 96 well plates coated
with primer pairs directed against components of the S1P system (SPHK1, SPHK2, S1P recep-
tors (S1PR1, S1PR2, S1PR3, S1PR4, S1PR5) and the S1P-degrading enzymes SGPP1, SGPP2
and SGPL1. Three reference genes, glucose 6-phosphate dehydrogenase (G6PD), hypoxanthine
Table 1. Patient demographics.
Controls Control Cur-Smoker COPD COPD Cur-smoker COPD Ex-Smoker
Number (n) 10 7 20 10 10
Age (yr) 56.5(26–71) 36(28–46) 66.5(42–86) 60(42–75) 74(49–86)
Smoking(cur/ex/no) 0/6/4 0/0/7 10/10/0 10/0/0 0/10/0
Gender (M/F) 6/4 2/5 14/6 5/5 9/1
Lung Cancer (y/n) 0/10 0/7 10/10 4/6 6/4
Type of Lung Cancer (NSCLC/SCLC) 0/0 0/0 10/0 4/0 6/0
Type of NSCLC (adenos /squa/ larg) 0/0 0/0 3/7/0 1/3/0 2/4/0
Radiation therapy (cur/pre/no) 0/0/10 0/0/7 1/2/7 0/1/3 1/1/4
Chemotherapy (cur/pre/no) 0/0/10 0/0/7 0/1/9 0/0/4 0/1/5
Glucocorticoid treatment (y/n) 0/10 0/0/7 0/0/10 0/0/4 0/0/6
Pky 4(0–28) 17.5(4–35) 40(10–75)* 50(10–50)* 25(17–75)*
fev1 106(71–120) 97(82–107) 76.5(47–113)* 78(47–113)* 76(67–90)*
fev1/fvc 80(70–88) 84(72–87) 63(49–69)* 62(50–67)* 64(49–69)*
Data are presented as number, or median and data range. COPD: chronic obstructive pulmonary disease; Smoking history: cur: current, ex: ex-smokers,
no: never smoked; Lung Cancer: presence of lung cancer; NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer; Type of NSCLC: adeno:
adenocarcinoma, squa: squamous cell carcinoma, larg: large cell carcinoma; Radiation therapy: cur: current, pre: previous exposure, no: never exposed;
Chemotherapy: cur: current, pre: previous exposure, no: never exposed; Pky: smoking pack years;fev1: forced expiratory volume in one second, % pred:
percentage of predicted; fvc: forced vital capacity.
*: signiﬁcant difference from control group, p<0.05. Note that one COPD patient was classiﬁed as ‘mild COPD’, with a fev1/fvc of 67.
doi:10.1371/journal.pone.0122771.t001
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phosphoribosyl transferase 1 (HPRT1) and ribosomal protein L13a (RPL13A) were used in the
array for data normalization. The efficiency and reliability of the PCR reaction was assessed by
determining the efficiency of the reverse transcriptase reaction by Reverse-transcription con-
trol (RTC) determining, the efficiency of polymerase chain reaction itself by positive PCR con-
trol (PPC), and DNA contamination in the reaction by genomic DNA control (HGDC).
Functional associations between sphingosine signalling system
components and alveolar macrophage phagocytic ability in COPD
Phagocytosis of apoptotic cells was measured as previously reported [3,4,30]. Briefly, 16HBE
bronchial epithelial cell targets were maintained in continuous culture, induced to apoptosis
using UV, then labelled with sytox orange (Molecular Probes, Oregon, USA). The apoptotic
cells were incubated with macrophages at a ratio of 10:1 for 1.5h. Non-adhered cells were
removed and macrophages removed by gentle pipetting, following 5min incubation with
500uL ice-cold phosphate buffered saline (PBS). Macrophages that had ingested apoptotic cells
were stained with CD13 phycoerythrin cyanine-7 (PE-Cy7) (BD Biosciences, San Jose CA,
USA)), autofluorescence was quenched with trypan blue and 30,000 total events per tube were
acquired immediately using a FACSCanto II Flow Cytometer (BD Biosciences). Macrophages
were identified based on autofluorescence properties and staining with CD13. The percentage
of the macrophages ingesting apoptotic cells was recorded.
To further elucidate functional effect of increased S1PR5 on macrophage phagocytic ability,
we performed the phagocytosis assay in the presence of varying concentrations of Suramin
(Sigma Aldrich, Castle Hill, NSW, Australia), an antagonist of S1PR3 and S1PR5 [31]. Suramin
at concentrations of 10nM to 10μMwas added for 30min prior to the phagocytosis assay.
Statistical analysis
Analysis was performed using SPSS statistic software (SPSS Inc. IBM Chicago, USA) and the
two-sample Wilcoxon rank sum test, or the Kruskal-Wallis test for analyses of more than two
groups. Correlation with lung function, smoking, age, gender and presence of lung cancer on
mRNA expression levels of SPHK/S1P system genes were determined using data from all sub-
jects and Pearson’s correlation coefficient with significance set at p<0.05.
Results
Characterization of expression profile of the S1P system in alveolar
macrophages in healthy subjects
The mRNA expression levels of the components of the S1P system in alveolar macrophages
from healthy individuals are unknown. We therefore compared the relative mRNA expression
levels of the SPHK/S1P system genes in alveolar macrophages obtained from healthy control
subjects (n = 10, Fig 1). All components of the S1P system were expressed in alveolar macro-
phages. We found no significant difference in the relative mRNA expression levels between the
S1P synthesizing enzymes, SPHK1 and2. In contrast, the S1P degradation enzymes, SGPP1,
SGPP2 and SPGL1 were differentially expressed. SGPP1 showed the highest, while SGPP2 had
the lowest relative expression level. There were large differences in relative-mRNA expression
levels among S1P receptors, with S1PR4 being the predominant subtype while S1PR5 showed
the lowest expression level. The rank order of mRNA expression levels of all receptors from the
high to low was S1PR4>S1PR2>S1PR1>S1PR3>S1PR5.
Sphingosine-1-Phosphate System in COPDMacrophages
PLOS ONE | DOI:10.1371/journal.pone.0122771 October 20, 2015 5 / 21
Characterization of expression profile of the sphingosine system in
alveolar macrophages in COPD
There was significantly higher mRNA-expression of both SPHK1&SPHK2 in alveolar macro-
phages from COPD patients (3.5 and 2.1fold increase respectively) compared to healthy con-
trols (Fig 2). To assess the effect of smoking, the expression of SPHK was assessed in alveolar
macrophages of healthy current smokers and current- or ex- smoker COPD patients. Com-
pared to non-smoking individuals, a significantly higher relative mRNA expression of SPHK1
was found in current healthy smokers (6-fold increase) and current-smoker COPD patients
(4.8-fold increase) compared to control subjects (Fig 2A). Significantly higher mRNA expres-
sion levels for SPHK2 were also found in current healthy smokers (4.4-fold increase) and cur-
rent-smoker COPD subjects (2.3-fold increase) (Fig 2B). No significant changes in SPHK1 or
SPHK2 expression were found in ex-smoker COPD patients, consistent with an effect of smoke
rather than COPD disease on the relative expression levels of this SPHK isoform in alveolar
macrophages.
Significantly higher mRNA expression levels for S1PR2 and S1PR5 were present in alveolar
macrophages from COPD subjects (4.3 and 14.6 fold increase respectively) compared to
healthy controls (Fig 3). No significant differences were found between S1PR1, S1PR3 and
S1PR4 and healthy controls (data not shown).
To assess the effect of smoking, the expression of S1P receptors was assessed in alveolar
macrophages from healthy current smokers and current- or ex- smoker COPD patients. We
found significantly higher mRNA expression for S1PR2 in the healthy current smokers
(9.3-fold increase p<0.05 vs control) and current-smoker COPD patients (6.1-fold increase
p<0.05 vs control) compared to healthy controls (Fig 3A). Interestingly, no difference was
found between ex-smoker COPD subjects and control subjects. In contrast, we observed signif-
icantly higher S1PR5mRNA levels in alveolar macrophages from both current- and ex-smoker
COPD patients compared to control subjects (n = 10, p<0.05 vs control, Fig 3B). The basal
very low S1PR5 expression was 32-fold higher in alveolar macrophages from ex-smoker COPD
Fig 1. Relative mRNA expression levels of SPHK/S1P system genes in alveolar macrophages across
normal subjectsc (N = 10). Box plots present median ± 25th and 75th percentiles (solid box) with the 10th
and 90th percentiles shown by whiskers outside the box. The Ct values were subtracted from 20, so that
higher values represent higher mRNA expression levels.
doi:10.1371/journal.pone.0122771.g001
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patients and 5.4-fold higher from current-smoker COPD subjects compared to health controls.
In addition there was no difference in the relative S1PR5 expression levels between healthy
smokers and non-smokers (Fig 3B), suggesting a COPD disease-specific effect rather than a
cigarette smoke effect. No difference was found in S1PR1, S1PR3 and S1PR4mRNA expression
in healthy current smokers and current- or ex- smoker COPD patients compared to healthy
controls (data not shown).
Significantly higher mRNA expression of SGPL1 was found in COPD alveolar macrophages
compared to cells from control subjects (4.5-fold increase p<0.05 COPD vs. control, Fig 4A).
No significant differences were found between groups for either SGPP1 or SGPP2 (Fig 4B and
4C. However when we split the COPD on the basis of their smoking status we found signifi-
cantly higher expression of SGPP2mRNA in alveolar macrophages from current-smoker
COPD subjects compared to healthy control subjects (6.1-fold increase p<0.05 vs control, Fig
4). In contrast, no significant differences were found in SGPP2 expression in either the ex-
smoker COPD group or, healthy current smokers vs. healthy non-smoking controls.
A non-significant trend toward higher expression of SGPL1mRNA was found in healthy
current smokers (p = 0.08) and in both ex-smoker and current-smoker COPD subjects
(p = 0.06 for both) compared to control subjects. No significant differences were found in rela-
tive mRNA expression for SGPP1 between healthy current smokers, ex-smoker COPD subjects
and current smoker COPD subjects compared to control subjects (Data not shown).
Fig 2. Relative mRNA expression of the S1P synthesizing enzymes, SPHK1, and SPHK2 in alveolar macrophages. (A) Significantly higher mRNA
expression of SPHK1 was noted in current healthy smokers (6-fold increase), current smoker COPD (4.8-fold increase) and total COPD (3.5-fold increase)
compared to control subjects (*p<0.05 vs control). No significant increase of SPHK1was found in alveolar macrophages isolated from ex-smoker COPD
patients. (B) Significantly higher mRNA expression of SPHK2 in current healthy smokers (4.4-fold increase), current smoker COPD(2.3-fold increase) and in
the total COPD group (2.1-fold increase) versus control subjects (*p<0.05 vs control) was found. No significant increase in SPHK2 was found in ex-smoker
COPD subjects compared to control subjects. Data presented as box plots as described in Fig 1. The Ct values were subtracted from 20 so that higher values
mean higher mRNA expression levels. Data presented as box plots as described in Fig 1. The Ct values were subtracted from 20 so that higher values
represent higher mRNA expression levels.
doi:10.1371/journal.pone.0122771.g002
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Functional associations between S1P signalling system components
and alveolar macrophage phagocytic ability in COPD
To assess the functional relevance of our findings with regard to macrophage phagocytic func-
tion we investigated the association between phagocytosis and expression pattern of the S1P
signalling system components. Consistent with our previous reports [3–7], a significantly
reduced ability to phagocytose apoptotic cells was observed in alveolar macrophages from
COPD patients in comparison to healthy control macrophages (mean±SEM, COPD 12.62
±2.43% vs controls 20.98±1.98% p = 0.004, Fig 5A. For 13 COPD subjects, a strong negative
correlation was found between SPHK1, S1PR3 and S1PR5mRNA expression levels and the
ability of alveolar macrophages to phagocytose apoptotic cells (SPHK1 r = -0.59, p<0.05;
S1PR3 r = -0.70, p<0.05; S1PR5 r = -0.87 p<0.05; SPHK1 data presented in Fig 5B. No signifi-
cant associations were found between the presence of lung cancer and macrophage phagocytic
ability (r = -0.471, p = 0.098).
Phagocytosis of apoptotic cells was dose dependently increased by the addition of the S1PR3
and S1PR5 agonist Suramin, with a maximum effect at a concentration of 1uM (Fig 6).
Associations between S1P signalling system components in alveolar
macrophages
Since the components of the SPHK/S1P system are part of a combined signalling system, we
analysed correlations between expressions of the various components. A strong positive corre-
lation between the relative mRNA expression levels was observed for SPHK1 and SPHK2
(r = 0.62, p<0. 05) (Fig 7A. In addition a strong positive correlation was found between S1P
Fig 3. Relative mRNA expression levels of S1PR2 and S1PR5 in alveolar macrophages. (A) Significantly higher mRNA expression levels of S1PR2 in
current healthy smokers (9.3-fold increase), current smoker COPD subjects (6.1-fold increase) and in the total COPD group (4.3-fold increase) versus control
subjects (*p<0.05 vs control) was found. No significant increase of S1PR2was found in ex-smoker COPD patients compared to control subjects. (B)
Significantly higher mRNA expression of S1PR5 was noted in in ex-smoker COPD subjects (32-fold increase), current smoker COPD subjects (5.4-fold
increase) and in the COPD group (14.6-fold increase) versus healthy control subjects (*p<0.05 vs control). Data presented as box plots as described in Fig 1.
The Ct values were subtracted from 20 so that higher values mean higher mRNA expression levels.
doi:10.1371/journal.pone.0122771.g003
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receptor subtypes e.g. S1PR1 and S1PR5 (r = 0.55, p<0.05); S1PR2 and S1PR4 (r = 0.79,
p<0.05; Fig 7B & 7C. We also noted a strong positive correlation between SPHK1 and S1PR2
(r = 0.81, p<0.05). There were positive correlations between the S1P degradation enzymes;
SGPP1 significantly correlated with SGPP2 (r = 0.38, p<0.05) (Fig 7D; SGPL1 significantly
Fig 4. Relative mRNA expression of S1P degradation enzymes in alveolar macrophages. (A) Significantly higher mRNA expression of SGPL1 in COPD
patients (4.5-fold increase) versus control subjects (*p<0.05 vs control). No significant increase of SGPL1was found in current smoker COPD, ex-smoker
COPD or healthy current smokers. (B) Significantly higher mRNA expression levels of SGPP2 in current smoker COPD patients (6.1-fold increase) versus
control subjects (*p<0.05 vs control) was noted. No significant increase of SGPP2was found in ex-smoker COPD subjects or healthy current smokers Data
presented as box plots as described in Fig 1. The Ct values were subtracted from 20 so that higher values mean higher mRNA expression levels.
doi:10.1371/journal.pone.0122771.g004
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Fig 5. (A) Phagocytosis of apoptotic 16HBE airway epithelial cells (AEC) by alveolar macrophages
from chronic obstructive pulmonary disease (COPD) subjects and controls.Compared to alveolar
macrophages from healthy controls, macrophages from COPD patients had a significantly reduced ability to
phagocytose apoptotic 16HBE epithelial cells (*p<0.05 vs control). (B) Correlation between the relative
mRNA expression of SPHK1 and% efferocytosis. There was a significant correlation between
efferocytosis and mRNA expression of SPHK1 (p<0.05). The correlation coefficients are listed in the results.
doi:10.1371/journal.pone.0122771.g005
Sphingosine-1-Phosphate System in COPDMacrophages
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correlated with both SGPP1 and SGPP2 (r = 0.60, p<0.05 and r = 0.54, p<0.05 respectively; Fig
7E & 7F).
Associations between S1P signalling system components and fev1,
fev1/fvc, smoking status, pack years, age, gender, presence of cancer,
type of cancer and previous or ongoing chemotherapy and/or
radiotherapy
A strong negative correlation was found between lung function (fev1) and mRNA expression
levels of SPHK1, S1PR1, S1PR3 and S1PR5 in alveolar macrophages (SPHK1 r = -0.49, p<0.05;
S1PR1 r = -0.44 p<0.05; S1PR3, r = -0.45, p<0.05; S1PR5 r = -0.55, p<0.05; Fig 8), with a trend
observed for both SGPL1 and SGPP2 with fev1 (SGPL1 r = -0.32, p = .078; SGPP2 r = -0.37, p =
.091; Fig 8). Furthermore a negative correlation was observed between the fev1/fvc ratio, a fur-
ther indicator of lung function, and mRNA expression levels of S1PR5 and S1PR3 (S1PR5 r =
-0.61 p<0.05; S1PR3 r = -0.52 p<0.05), with a trend observed between SPHK1 and fev1/fvc (r =
-0.33, p = .063).
We found a significant positive correlation between smoking status and relative mRNA
expression levels of both SPHK isoforms, S1PR2, S1PR4 and SGPP2 (SPHK1r = 0.41, p<0.05;
SPHK2 r = 0.38, p<0.05; S1PR2 r = 0.36, p<0.05, S1PR4 r = 0.35, p<0.05; SGPP2 r = 0.39,
p<0.05). There were significant positive correlations between age and mRNA expression levels
of S1PR1 and S1PR3 (S1PR1 r = 0.39, p<0.05; S1PR3 r = 0.45, p<0.05). Moreover a high posi-
tive correlation was revealed between mRNA expression levels of SPHK2 and S1PR5 and smok-
ing pack years (SPHK2 r = 0.36, p<0. 05; S1PR5 r = 0.54, p<0. 05). No correlation was found
between gender and any of the S1P system mRNA levels. The only significant correlation
between the presence of cancer and S1P system mRNA expression levels was for S1PR3 that
Fig 6. Effects of antagonising S1PR3 and S1PR5with Suramin. To further elucidate functional effect of
increased S1PR5 on macrophage phagocytic ability, we performed the phagocytosis assay in the presence
of varying concentrations of Suramin, an antagonist of S1PR3 and S1PR5. Suramin at concentrations of
10nM to 10μMwere added for 30 min prior to the phagocytosis assay. We noted a significant (p<0.05)
increase in phagocytosis of apoptotic cells in the presence of Suramin.
doi:10.1371/journal.pone.0122771.g006
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Fig 7. Correlations between relative mRNA expression of various components of the S1P signalling system in alveolar macrophages. (A)
correlation between SPHK1 and 2, p<0.05; (B) correlation between S1PR1 and S1PR5, p<0.05; (C) correlation between S1PR2 and S1PR4, p<0.05; (D)
correlation between SGPP1 and SGPP2 p<0.05; (E) correlation between SGPL1 and SGPP1 p<0.05; (F) SGPL1 and SGPP2. The correlation coefficients are
listed in the results.
doi:10.1371/journal.pone.0122771.g007
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showed a positive correlation with the presence of cancer independent of COPD status
(r = 0.41, p<0.05). Moreover, no significant associations were found between S1P system
mRNA expression levels with types of lung cancer or exposure to chemotherapy and/or
radiotherapy.
Fig 8. Correlations between the relative mRNA expression of various components of the S1P signalling system and lung function (fev1). Significant
(p<0.05) correlations were found between fev1 and (A) SPHK1 (B) S1PR1 (C) S1PR3, (D) S1PR5, p<0.05. The correlation coefficients are listed in the
results.
doi:10.1371/journal.pone.0122771.g008
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Investigation of the effect of cigarette smoke extract on the expression of
SPHK1, SPHK2, S1PR2, S1PR5 and SGPP2 in THP-1 macrophages in
vitro
Assessment of S1P system genes showed variation according to their passages, with expression
pattern comparable to normal human alveolar macrophages between passages 6 to 20. To con-
firm the effects of cigarette smoke on macrophage expression of SPHK1, SPHK2, S1PR2, S1PR5
and SGPP2 we determined the expression levels of the SPHK/S1P system in THP-1 macro-
phages exposed to 10% cigarette smoke extract for 24h. Consistent with the alveolar macro-
phages from human smoker COPD subjects, we noted significantly higher relative mRNA
expression of SPHK1, SPHK2, S1PR5 and S1PR2 whereas there was no increase in expression
of SGPP2 and SGPL1 (n = 7experiments p<0.05, Fig 9).
Discussion
In recent years it has become evident that alveolar macrophages play a vital role in the patho-
physiology and development of COPD [31]. Macrophages modulate and control levels of
inflammation; however, the macrophage-dependent inflammatory haemostasis is defective in
COPD [31]. One of the major causes of this defect is thought to be a reduced ability of alveolar
macrophages to phagocytose apoptotic cells and bacteria [3,32] which contributes to ongoing
inflammation in lungs of these patients [8,33]. Several studies have reported changes in candi-
date molecules that may at least partially contribute to the defective efferocytosis in COPD,
although it is becoming clear that a more complex network of molecules rather than a single
molecule is the more likely cause of the reduced efferocytosis [34,35]. In particular, identifica-
tion of molecule(s) that are affected in COPD irrespective of smoking status would be an
important strategy toward identification of new macrophage-targeted treatments for COPD.
Previous studies have identified the S1P system as a candidate for macrophage dysfunction.
McQuiston et al. showed that the S1P-mediated increase in phagocytosis occurred in an anti-
body-dependent manner [23,36]. The antibody-mediated pathway is commonly linked to
phagocytosis of pathogen; however, it became clear in the last decade that apoptotic cells can
also become opsonized with naturally occurring IgM auto antibodies which facilitate their
internalization [37–40] This mechanism is particularly efficient when combined with the com-
plement [40]. Petrusca et al. reported that up-regulation of the S1P precursor ceramide inhib-
ited the alveolar macrophage-mediated clearance of apoptotic cells [24]. A further study on
murine microglia, resident macrophage-like cells of the CNS which are involved in phagocyto-
sis and inflammatory responses, showed the involvement of SPHK1 signalling in their func-
tions [41]. These studies, however, were focused on single components of the S1P system, and
to the best of our knowledge, there is no study that has comprehensively studied the combina-
tion of synthesizing, degrading enzymes and receptors in human alveolar macrophages in
COPD.
S1P, the product of SPHK1 and 2 has been implicated in many biological functions in the
cell, including survival, proliferation and migration, and macrophage phagocytic function
[16,20,42,43]. In the present study, the expression of both SPHK1 and SPHK2mRNAs was sig-
nificantly increased in alveolar macrophages from healthy smokers and current-smoker COPD
subjects, with no changes found in macrophages obtained from ex-smoker COPD subjects.
This indicates a close association between smoking and expression of S1P synthesizing
enzymes. The effect of cigarette smoke was further highlighted by a significant increase in
SPHK1 in the model of cigarette smoke-exposed THP-1 macrophages. Furthermore analysis of
expression and patient data showed and a positive correlation between SPHK1 and smoking
status. Smoking causes inflammation and inflammation is known to modulate SPHK1mRNA
Sphingosine-1-Phosphate System in COPDMacrophages
PLOS ONE | DOI:10.1371/journal.pone.0122771 October 20, 2015 14 / 21
Fig 9. mRNA expression of various components of the S1P signalling system in THP-1 macrophages following stimulation with 10% cigarette
smoke extract for 24h. *:Significant increase in mRNA expression of SPHK1, SPHK2,S1PR2, S1PR5, but no significant changes were found in SGPL1 and
SGPP2 compared to non-stimulated macrophages (p<0.05).
doi:10.1371/journal.pone.0122771.g009
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expression in animal macrophages [41,44,45]. In this study we showed for the first time the
response in SPHK1 in the context of COPD or cigarette smoking. Increased ceramide levels in
alveolar macrophages have been shown to impair their ability to phagocytose apoptotic cells
[24]. Ceramide is converted to sphingosine which is phosphorylated via SPHK1 and SPHK2 to
S1P [46]. It is thus possible that the higher mRNA expression levels of SPHK1 or SPHK2 in
alveolar macrophages in response to smoking reflect the response to high ceramide levels with
the aim to reduce ceramide concentration.
A finely-tuned balance between SPHK1 and SPHK2 expression and functions, with tissue
specificity has been reported [47]. For example, in rodent neuronal tissue there are higher levels
of SPHK2 compared to SPHK1 [48], whereas in murine lungs there is higher expression and
activity of SPHK1 [49,50]. It should be noted that the expression in the lung reflects many cell
types including endothelial, epithelial cells and macrophages. Interestingly in the present
study, we observed equal relative mRNA-expression levels for SPHK1 and SPHK2, and a corre-
lation between the two in alveolar macrophages from healthy controls. In contrast, the two
kinases were differentially expressed in alveolar macrophages from COPD subjects and
although both SPHK1 and SPHK2 separately correlated positively with smoking status, only
SPHK1 was found to be correlated with lung function suggesting a changed mRNA expression
and presumably a change in balance between the kinases and the potential involvement of
SPHK1 in smoking-related COPD disease progression.
S1P receptors are essential for S1P function [19]. Changes in expression of these receptors
have been reported in many cell types in various lung diseases including acute lung injury,
asthma, cystic fibrosis and COPD [51]. The distribution of the receptors has been shown to be
cell specific and affected differently in the various disease conditions [16]. The presence of S1P
receptors in macrophages has been well documented [20,52]; however, the presence and expres-
sion in human alveolar macrophages is less studied. The S1PR4 subtype showed the highest rela-
tive mRNA expression followed by the S1PR2 subtype. Consistent with our data for SPHKs, we
found that expression of S1PR2mRNA in alveolar macrophages increased with smoking, and
increased in both healthy current smokers and current-smoker COPD subjects, but was
unchanged in ex-smoker COPD subjects. In addition, our in vitro investigations revealed a sig-
nificant increase in S1PR2 in cigarette smoke extract exposed THP-1 macrophages, confirming
the direct effects of cigarette smoke on expression of this receptor. A potential role for this
receptor in phagocytosis was also shown by McQuiston et al who showed that treatment with
the dual S1PR2/4 antagonist JTE-013 affected the phagocytosis of Cryptococcus neoformans by
wild-type alveolar macrophages in contrast with the S1PR1 antagonists W146 or VPC 23901
[23,36]. In non-alveolar macrophages/monocytes activation of S1PR2 attenuated migration
[53]. This could relate to cigarette smoke-induced inhibition of macrophage function in alveoli.
S1PR2may also play a role in the activation of cytoskeletal-remodelling that occurs during effer-
ocytosis. The increased cigarette smoke-related S1PR2 expression by alveolar macrophages
found in our study was therefore surprising; however, we also noted a positive correlation
between S1PR2 and S1PR4. Efferocytosis occurs with extensive pseudopod extensions and is
dependent on the relative activation of Rho GTPases, Rac-1 and RhoA [54] that control actin
polymerisation and formation of lamellipodia that is required for macrophage engulfment of
apoptotic cells. We and others have shown that Rho activity is increased and Rac-1 activity
decreased, in macrophages in response to cigarette smoke [6,55,56]. Interestingly, expression of
S1PR4 protein has also been shown to activate RhoA in response to S1P stimulation in Chinese
hamster ovary (CHO) cells [57], and S1P has been shown to promote migration of cells express-
ing S1PR4 through activation Cdc42, a Rho family member [58]. The positive correlation we
found between S1PR2 and S1PR4 thus suggests that these receptors may potentially work in
concert to negatively affect the efferocytosis process in response to cigarette smoke.
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S1PR2 expression also induces increased macrophage accumulation in atherosclerosis pla-
que and promotion of inflammation in mice [59,60], and its increased expression could thus
also contribute to the macrophage accumulation that has been reported in current smokers
with or without COPD [61,62].
In contrast to the findings with SPHK1, SPHK2 and S1PR2, we found that S1PR5 was higher
in alveolar macrophages from both ex-smoker COPD and current smoker COPD subjects and
negatively correlated with both fev1 and fev/fvc indicating a possible involvement in COPD
progression that is at least to some extent independent of cigarette smoking. Unlike S1PR2,
there were no correlations between S1PR5 and smoking status, or with SPHK1 or SPHK2 or
S1PR2. Currently, the role of S1PR5 in macrophages is unclear, although our findings of a
strong negative correlation between expression of S1PR5 and phagocytosis of apoptotic cells
suggest that it may play an important role in this function and contribute to the defective mac-
rophage function in COPD. Several studies have shown that mRNA levels not always predict
protein expression. We therefore utilized a functional approach to assert the increase of S1PR5
and its effects on macrophage phagocytic ability. We used a S1PR3/5 antagonist suramin [31],
and found that phagocytosis was dose dependently increased with a maximum effect at 1uM
suramin. Taken together with our findings of significant associations between the increased
expression of SPHK, S1PR2 and S1PR5, and alveolar macrophage phagocytic ability in COPD,
these data support a functional effect of the increased gene expression of S1PR5. S1PR5 has
been reported to interact with Rho-G12/13 protein coupled Rho/ROCK signalling pathway in
oligodendrocyte precursor cells (OPCs) and appears to mediate their migration [63]. Although
we did not find significantly increased expression of S1PR1 in alveolar macrophages from
either smokers or COPD subjects, this receptor was found to be strongly correlated with
S1PR5. Taken together with our findings of a negative correlation with lung function and
phagocytosis of apoptotic cells, these data suggest that both receptors may be associated with
COPD progression and defective macrophage function in COPD either by a link between the
two or common downstream effectors. Consistent with this, a previous study showed that both
S1PR1 and S1PR5 enhanced microgliosis [64]. It is thus likely that the defective efferocytosis in
COPD that persists despite smoke cessation could be mediated by S1PR5, possibly in associa-
tion with S1PR1. Interestingly, in our previous study the relative mRNA for S1PR5 was signifi-
cantly lower in whole lung tissue of patients with COPD compared to controls without COPD
[16]. In the present study, however, alveolar macrophage-specific S1PR5 expression was
increased when comparing COPD vs. controls. This counterintuitive finding further highlights
the finely tuned balance and the tissue specificity of the sphingosine family, and stresses the
need to investigate not only whole lung tissue, but individual cell types of interest.
None of the controls in this study suffered from lung cancer whereas 60% of the COPD
patients did. We therefore correlated S1P system mRNA expression levels with the presence of
lung cancer. The only significant correlation however was for S1PR3 that showed a positive
correlation with the presence of cancer independent of COPD status, suggesting that the find-
ings in COPD subjects in our study were not influenced by the presence of lung cancer. A
potential limitation of the study is that we did not measure S1P levels in BALF as this would
have provided an additional understanding of smoke- and/or COPD-related changes in S1P
signalling.
S1P degradation enzymes, SGPP1, SGPP2 andSGPL1 are enzymes that metabolize S1P in
the cell and their importance comes from their role in controlling the levels of S1P in the cell,
excessive concentrations of which are detrimental to cell fate and functions [42,65] as well as
drug resistance and cancer [66]. In the present study, SGPL1 was found to be higher in alveolar
macrophages from COPD subjects while SGPP2 was higher in current-smoker COPD subjects
compared to healthy controls, with a trend towards a significant correlation between SGPP2
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and lung function. In parallel, we also found that cigarette smoke failed to increase mRNA lev-
els of SGPP2 and SGPL1 in our in vitro cell line experiments. Recently, SNP variants on SGPP2
in lung epithelial cells from adult smoker subjects found to be associated with vitamin D regu-
lations as well as and fev1 and fev/fvc ratio [67]. Furthermore, vitamin D-binding protein
(DBP) levels were found to be directly responsible for alveolar macrophage activation as well as
related to fev1 [68]. We also noted a non-significant trend for an increase in SGPL1, the other
S1P degradation enzyme, in healthy smokers and both and current-and ex-smoker COPD sub-
jects as well as a positive correlation with SGPP2, suggesting a link between these two enzymes
in alveolar macrophages in COPD. SGPP2 converts S1P to sphingosine which can be converted
back to ceramide and SGPL1 degrades S1P, which indirectly can favour an increase in ceramide
over S1P, so the increase in both degradation enzymes is likely to impact on the increasing cer-
amide levels and subsequent defect in alveolar macrophage efferocytosis ability. In addition,
the established link between COPD and vitamin D and alveolar macrophage function [69–71],
and the role of these enzymes in degradation of S1P [18] suggests a potential important indirect
role of SGPP2 and/or SGPL1 in the alveolar macrophage defect in COPD. Interestingly, a corre-
lation between SGPP1 and SGPL1 expression by alveolar macrophages was found in the pres-
ent study, further supporting a link between these two enzymes.
In conclusion, our data strongly support the role of the S1P signalling pathway in the defec-
tive alveolar macrophage function and resultant chronic inflammation that is present in the
airways of patients with COPD. In particular, we identified S1PR5 and S1P degradation
enzymes as mediators that are independently increased in alveolar macrophages in COPD,
independent of the presence of cigarette smoke and, importantly, a significant correlation
between S1PR5mRNA expression and lung function. These mediators are thus worthy of their
further investigation as macrophage-target therapeutic strategies for COPD and other chronic
inflammatory lung diseases.
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